156 related articles for article (PubMed ID: 28446318)
1. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
Wang Q; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
[TBL] [Abstract][Full Text] [Related]
2. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
Quintás-Cardama A; Kantarjian H; Cortes J
Cancer; 2009 Dec; 115(23):5382-93. PubMed ID: 19739234
[TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine for the treatment of chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
[TBL] [Abstract][Full Text] [Related]
5. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
Nazha A; Kantarjian H; Cortes J; Quintás-Cardama A
Expert Opin Pharmacother; 2013 Oct; 14(14):1977-86. PubMed ID: 23875628
[TBL] [Abstract][Full Text] [Related]
6. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
7. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
Lü S; Wang J
J Hematol Oncol; 2014 Jan; 7():2. PubMed ID: 24387717
[TBL] [Abstract][Full Text] [Related]
8. Omacetaxine mepesuccinate in chronic myeloid leukemia.
Al Ustwani O; Griffiths EA; Wang ES; Wetzler M
Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
[TBL] [Abstract][Full Text] [Related]
10. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
Chung C
Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
[TBL] [Abstract][Full Text] [Related]
11. Omacetaxine as an anticancer therapeutic: what is old is new again.
Wetzler M; Segal D
Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
[TBL] [Abstract][Full Text] [Related]
13. Omacetaxine mepesuccinate for the treatment of leukemia.
Kim TD; Frick M; le Coutre P
Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
[TBL] [Abstract][Full Text] [Related]
14. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
[TBL] [Abstract][Full Text] [Related]
16. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Narayanan V; Gutman JA; Pollyea DA; Jimeno A
Drugs Today (Barc); 2013 Jul; 49(7):447-56. PubMed ID: 23914353
[TBL] [Abstract][Full Text] [Related]
17. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
Visani G; Russo D; Ottaviani E; Tosi P; Damiani D; Michelutti A; Manfroi S; Baccarani M; Tura S
Leukemia; 1997 May; 11(5):624-8. PubMed ID: 9180282
[TBL] [Abstract][Full Text] [Related]
18. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Damlaj M; Lipton JH; Assouline SE
Expert Opin Drug Saf; 2016 Sep; 15(9):1279-86. PubMed ID: 27367461
[TBL] [Abstract][Full Text] [Related]
19. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
O'Brien S; Kantarjian H; Keating M; Beran M; Koller C; Robertson LE; Hester J; Rios MB; Andreeff M; Talpaz M
Blood; 1995 Nov; 86(9):3322-6. PubMed ID: 7579434
[TBL] [Abstract][Full Text] [Related]
20. Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate).
Novotny L; Al-Tannak NF; Hunakova L
Neoplasma; 2016; 63(4):495-503. PubMed ID: 27268912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
